Pharmaceutical regulation in Europe and its impact on corporate R&D

Stephan Eger () and Jörg Mahlich ()

Health Economics Review, 2014, vol. 4, issue 1, 1-9

Abstract: The results can be interpreted as further evidence of the deteriorating effect of regulation on firm’s incentives to invest in R&D. Copyright Eger and Mahlich; licensee Springer. 2014

Keywords: Pharmaceutical Industry; R&D investments; Regulation (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://hdl.handle.net/10.1186/s13561-014-0023-5 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:4:y:2014:i:1:p:1-9:10.1186/s13561-014-0023-5

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-014-0023-5

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().